Edwards Lifesciences (EW) Cash & Current Investments (2009 - 2026)

Edwards Lifesciences has reported Cash & Current Investments for 18 years, with the latest figure at $3.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 5.82% year-over-year to $3.7 billion; the trailing twelve-month figure through Mar 2026 stood at $3.7 billion (down 5.82% YoY), and the FY2025 full-year result was $4.2 billion, up 6.3% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $3.7 billion, down from $4.2 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $4.4 billion in Q3 2024, with the low at $1.2 billion in Q4 2022.
• Average Cash & Current Investments over 5 years is $2.6 billion, with a median of $1.9 billion recorded in 2023.
• Year-over-year, Cash & Current Investments retreated 17.66% in 2022 and jumped 143.5% in 2024.
• Tracing EW's Cash & Current Investments over 5 years: stood at $1.2 billion in 2022, then soared by 35.19% to $1.6 billion in 2023, then jumped by 143.5% to $4.0 billion in 2024, then gained by 6.3% to $4.2 billion in 2025, then dropped by 13.13% to $3.7 billion in 2026.
• The last three Cash & Current Investments figures came in at $3.7 billion (Q1 2026), $4.2 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.

Peer Comparison